GE HealthCare Reports the P-I Study Data of its Macrocyclic Manganese-Based MRI Contrast Agent
Shots:
- GE HealthCare has concluded the P-I clinical evaluation of first-of-its-kind manganese-based macrocyclic MRI contrast agent and highlighted the data at CMR 2024
- Results depicted that the agent was well-tolerated without any SAEs or DLTs. The data will form the basis of further advancement
- The manganese-based agent has similar diagnostic performance & comparable relaxivity to gadolinium-based agents, is naturally occurring & efficiently eliminated from the body, indicating its potential to become an alternative to gadolinium
Ref: GE Healthcare | Image: GE Healthcare
Related News:- GE HealthCare to Expand its AI-Based Portfolio Through the Acquisition of Intelligent Ultrasound’s Business Unit
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
